Literature DB >> 25171398

Neutralizing the HIV reservoir.

Matthew D Marsden1, Jerome A Zack2.   

Abstract

Halper-Stromberg et al. use a humanized mouse model to demonstrate that broadly neutralizing antibodies, when administered with a combination of HIV latency activators, can reduce persistent HIV reservoirs, as measured by plasma virus rebound. Their results support the use of broadly neutralizing antibodies in HIV-reservoir-purging strategies.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25171398      PMCID： PMC4182933          DOI： 10.1016/j.cell.2014.08.010

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  10 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  HIV latency in the humanized BLT mouse.

Authors:  Matthew D Marsden; Michael Kovochich; Nuttee Suree; Saki Shimizu; Roshni Mehta; Ruth Cortado; Gregory Bristol; Dong Sung An; Jerome A Zack
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 3.  HIV/AIDS eradication.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Bioorg Med Chem Lett       Date:  2013-05-18       Impact factor: 2.823

4.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

6.  Infection of the SCID-hu mouse by HIV-1.

Authors:  R Namikawa; H Kaneshima; M Lieberman; I L Weissman; J M McCune
Journal:  Science       Date:  1988-12-23       Impact factor: 47.728

7.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

8.  Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse.

Authors:  Shailesh K Choudhary; Nancie M Archin; Manzoor Cheema; Noelle P Dahl; J Victor Garcia; David M Margolis
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

9.  Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.

Authors:  Ariel Halper-Stromberg; Ching-Lan Lu; Florian Klein; Joshua A Horwitz; Stylianos Bournazos; Lilian Nogueira; Thomas R Eisenreich; Cassie Liu; Anna Gazumyan; Uwe Schaefer; Rebecca C Furze; Michael S Seaman; Rab Prinjha; Alexander Tarakhovsky; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Cell       Date:  2014-08-14       Impact factor: 41.582

10.  Antibody-based protection against HIV infection by vectored immunoprophylaxis.

Authors:  Alejandro B Balazs; Joyce Chen; Christin M Hong; Dinesh S Rao; Lili Yang; David Baltimore
Journal:  Nature       Date:  2011-11-30       Impact factor: 49.962
  10 in total
  9 in total

Review 1.  Towards HIV-1 remission: potential roles for broadly neutralizing antibodies.

Authors:  Ariel Halper-Stromberg; Michel C Nussenzweig
Journal:  J Clin Invest       Date:  2016-01-11       Impact factor: 14.808

2.  Experimental Approaches for Eliminating Latent HIV.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  For Immunopathol Dis Therap       Date:  2015

3.  Mitochondrial Impairment in Well-Suppressed Children with Perinatal HIV-Infection on Antiretroviral Therapy.

Authors:  Jing Shen; Afaaf Liberty; Stephanie Shiau; Renate Strehlau; Sheila Pierson; Faeezah Patel; LiQun Wang; Megan Burke; Avy Violari; Ashraf Coovadia; Elaine J Abrams; Stephen Arpadi; Marc Foca; Louise Kuhn
Journal:  AIDS Res Hum Retroviruses       Date:  2019-07-15       Impact factor: 2.205

Review 4.  Studies of retroviral infection in humanized mice.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Virology       Date:  2015-02-11       Impact factor: 3.616

Review 5.  Humanized Mouse Models for Human Immunodeficiency Virus Infection.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  Annu Rev Virol       Date:  2017-07-26       Impact factor: 10.431

Review 6.  Broadly neutralizing antibodies in HIV-1 treatment and prevention.

Authors:  Rajesh Kumar; Huma Qureshi; Suprit Deshpande; Jayanta Bhattacharya
Journal:  Ther Adv Vaccines Immunother       Date:  2018-10-12

Review 7.  HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.

Authors:  Loredana Sarmati; Gabriella D'Ettorre; Saverio Giuseppe Parisi; Massimo Andreoni
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

Review 8.  Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.

Authors:  Casey K Hua; Margaret E Ackerman
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561

9.  In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.

Authors:  Matthew D Marsden; Brian A Loy; Xiaomeng Wu; Christina M Ramirez; Adam J Schrier; Danielle Murray; Akira Shimizu; Steven M Ryckbosch; Katherine E Near; Tae-Wook Chun; Paul A Wender; Jerome A Zack
Journal:  PLoS Pathog       Date:  2017-09-21       Impact factor: 6.823
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.